ID   ADCY5_HUMAN             Reviewed;        1261 AA.
AC   O95622; B7Z8A6; Q7RTV7; Q8NFM3;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 3.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=Adenylate cyclase type 5;
DE            EC=4.6.1.1 {ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:24700542, ECO:0000269|PubMed:26206488};
DE   AltName: Full=ATP pyrophosphate-lyase 5;
DE   AltName: Full=Adenylate cyclase type V;
DE   AltName: Full=Adenylyl cyclase 5;
DE            Short=AC5 {ECO:0000303|PubMed:26206488};
GN   Name=ADCY5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-1261 (ISOFORM 1).
RC   TISSUE=Heart;
RX   PubMed=12503609; DOI=10.1081/RRS-120014589;
RA   Ludwig M.G., Seuwen K.;
RT   "Characterization of the human adenylyl cyclase gene family: cDNA,
RT   gene structure, and tissue distribution of the nine isoforms.";
RL   J. Recept. Signal Transduct. 22:79-110(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 560-664 (ISOFORM 1).
RC   TISSUE=Heart muscle;
RX   PubMed=10481931; DOI=10.1016/S0009-8981(99)00067-4;
RA   Raimundo S., Giray J., Volff J.-N., Schwab M., Altenbuchner J.,
RA   Ratge D., Wisser H.;
RT   "Cloning and sequence of partial cDNAs encoding the human type V and
RT   VI adenylyl cyclases and subsequent RNA-quantification in various
RT   tissues.";
RL   Clin. Chim. Acta 285:155-161(1999).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION BY RAF1, INTERACTION WITH RAF1, AND ENZYME REGULATION.
RX   PubMed=15385642; DOI=10.1124/mol.66.4.;
RA   Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.;
RT   "Raf kinase activation of adenylyl cyclases: isoform-selective
RT   regulation.";
RL   Mol. Pharmacol. 66:921-928(2004).
RN   [6]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=24740569; DOI=10.2337/db13-1607;
RA   Hodson D.J., Mitchell R.K., Marselli L., Pullen T.J., Gimeno Brias S.,
RA   Semplici F., Everett K.L., Cooper D.M., Bugliani M., Marchetti P.,
RA   Lavallard V., Bosco D., Piemonti L., Johnson P.R., Hughes S.J., Li D.,
RA   Li W.H., Shapiro A.M., Rutter G.A.;
RT   "ADCY5 couples glucose to insulin secretion in human islets.";
RL   Diabetes 63:3009-3021(2014).
RN   [7]
RP   INTERACTION WITH GNAS; GNB1 AND GNG2, FUNCTION, CATALYTIC ACTIVITY,
RP   ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=26206488; DOI=10.1124/mol.115.099556;
RA   Brand C.S., Sadana R., Malik S., Smrcka A.V., Dessauer C.W.;
RT   "Adenylyl cyclase 5 regulation by Gbetagamma involves isoform specific
RT   use of multiple interaction sites.";
RL   Mol. Pharmacol. 88:758-767(2015).
RN   [8]
RP   VARIANT FDFM THR-726.
RX   PubMed=22782511; DOI=10.1001/archneurol.2012.54;
RA   Chen Y.Z., Matsushita M.M., Robertson P., Rieder M., Girirajan S.,
RA   Antonacci F., Lipe H., Eichler E.E., Nickerson D.A., Bird T.D.,
RA   Raskind W.H.;
RT   "Autosomal dominant familial dyskinesia and facial myokymia: single
RT   exome sequencing identifies a mutation in adenylyl cyclase 5.";
RL   Arch. Neurol. 69:630-635(2012).
RN   [9]
RP   VARIANT FDFM TRP-418, CHARACTERIZATION OF VARIANTS FDFM TRP-418 AND
RP   THR-726, FUNCTION, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=24700542; DOI=10.1002/ana.24119;
RA   Chen Y.Z., Friedman J.R., Chen D.H., Chan G.C., Bloss C.S.,
RA   Hisama F.M., Topol S.E., Carson A.R., Pham P.H., Bonkowski E.S.,
RA   Scott E.R., Lee J.K., Zhang G., Oliveira G., Xu J.,
RA   Scott-Van Zeeland A.A., Chen Q., Levy S., Topol E.J., Storm D.,
RA   Swanson P.D., Bird T.D., Schork N.J., Raskind W.H., Torkamani A.;
RT   "Gain-of-function ADCY5 mutations in familial dyskinesia with facial
RT   myokymia.";
RL   Ann. Neurol. 75:542-549(2014).
CC   -!- FUNCTION: Catalyzes the formation of the signaling molecule cAMP
CC       in response to G-protein signaling (PubMed:15385642,
CC       PubMed:26206488, PubMed:24700542). Mediates signaling downstream
CC       of ADRB1 (PubMed:24700542). Regulates the increase of free
CC       cytosolic Ca(2+) in response to increased blood glucose levels and
CC       contributes to the regulation of Ca(2+)-dependent insulin
CC       secretion (PubMed:24740569). {ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:24700542, ECO:0000269|PubMed:24740569,
CC       ECO:0000269|PubMed:26206488}.
CC   -!- CATALYTIC ACTIVITY: ATP = 3',5'-cyclic AMP + diphosphate.
CC       {ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:24700542,
CC       ECO:0000269|PubMed:26206488}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15385642};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:15385642};
CC       Note=Binds 2 magnesium ions per subunit. Is also active with
CC       manganese (in vitro). {ECO:0000250|UniProtKB:P30803};
CC   -!- ENZYME REGULATION: Activated by forskolin (PubMed:24700542).
CC       Activated by GNAS. Activity is further increased by interaction
CC       with the G-protein beta and gamma subunit complex formed by GNB1
CC       and GNG2 (PubMed:26206488). Is not activated by calmodulin.
CC       Inhibited by adenosine and ATP analogs. Inhibited by calcium ions,
CC       already at micromolar concentrations (By similarity).
CC       Phosphorylation by RAF1 results in its activation
CC       (PubMed:15385642). {ECO:0000250|UniProtKB:P30803,
CC       ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:26206488}.
CC   -!- SUBUNIT: Interacts with GNAS, GNB1 and GNG2 (PubMed:26206488).
CC       Part of a complex containing AKAP5, ADCY6, PDE4C and PKD2 (By
CC       similarity). Interacts with RAF1 (PubMed:15385642).
CC       {ECO:0000250|UniProtKB:P84309, ECO:0000269|PubMed:15385642,
CC       ECO:0000269|PubMed:26206488}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305|PubMed:15385642,
CC       ECO:0000305|PubMed:26206488}; Multi-pass membrane protein. Cell
CC       projection, cilium {ECO:0000250|UniProtKB:P84309}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O95622-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95622-2; Sequence=VSP_042914, VSP_042915;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in pancreas islets (at protein
CC       level). Detected in pancreas islets.
CC       {ECO:0000269|PubMed:24740569}.
CC   -!- DOMAIN: The protein contains two modules with six transmembrane
CC       helices each; both are required for catalytic activity. Isolated
CC       N-terminal or C-terminal guanylate cyclase domains have no
CC       catalytic activity, but when they are brought together, enzyme
CC       activity is restored. The active site is at the interface of the
CC       two domains. Both contribute substrate-binding residues, but the
CC       catalytic metal ions are bound exclusively via the N-terminal
CC       guanylate cyclase domain. {ECO:0000250|UniProtKB:P30803}.
CC   -!- PTM: Phosphorylated by RAF1. {ECO:0000269|PubMed:15385642}.
CC   -!- DISEASE: Dyskinesia, familial, with facial myokymia (FDFM)
CC       [MIM:606703]: A disorder characterized by predominantly perioral
CC       and periorbital myokymia, and face, neck and upper limb
CC       dystonic/choreic movements. Initially paroxysmal and worsened by
CC       stress, the dyskinetic episodes become nearly constant by the end
CC       of the third decade of life, but in some individuals, they may
CC       diminish in frequency and severity at older ages.
CC       {ECO:0000269|PubMed:22782511, ECO:0000269|PubMed:24700542}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl
CC       cyclase family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK303070; BAH13892.1; -; mRNA.
DR   EMBL; AC025571; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112503; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF497517; AAM94374.1; -; mRNA.
DR   EMBL; U65473; AAD00121.1; -; mRNA.
DR   EMBL; BK000371; DAA00057.1; -; mRNA.
DR   CCDS; CCDS3022.1; -. [O95622-1]
DR   CCDS; CCDS56274.1; -. [O95622-2]
DR   RefSeq; NP_001186571.1; NM_001199642.1. [O95622-2]
DR   RefSeq; NP_899200.1; NM_183357.2. [O95622-1]
DR   UniGene; Hs.593292; -.
DR   ProteinModelPortal; O95622; -.
DR   SMR; O95622; -.
DR   BioGrid; 106624; 14.
DR   STRING; 9606.ENSP00000419361; -.
DR   BindingDB; O95622; -.
DR   ChEMBL; CHEMBL3189; -.
DR   DrugBank; DB02587; Colforsin.
DR   GuidetoPHARMACOLOGY; 1282; -.
DR   iPTMnet; O95622; -.
DR   PhosphoSitePlus; O95622; -.
DR   BioMuta; ADCY5; -.
DR   MaxQB; O95622; -.
DR   PaxDb; O95622; -.
DR   PeptideAtlas; O95622; -.
DR   PRIDE; O95622; -.
DR   DNASU; 111; -.
DR   Ensembl; ENST00000309879; ENSP00000308685; ENSG00000173175. [O95622-2]
DR   Ensembl; ENST00000462833; ENSP00000419361; ENSG00000173175. [O95622-1]
DR   GeneID; 111; -.
DR   KEGG; hsa:111; -.
DR   UCSC; uc003egh.3; human. [O95622-1]
DR   CTD; 111; -.
DR   DisGeNET; 111; -.
DR   GeneCards; ADCY5; -.
DR   H-InvDB; HIX0003612; -.
DR   HGNC; HGNC:236; ADCY5.
DR   HPA; HPA017730; -.
DR   HPA; HPA077682; -.
DR   MalaCards; ADCY5; -.
DR   MIM; 600293; gene.
DR   MIM; 606703; phenotype.
DR   neXtProt; NX_O95622; -.
DR   OpenTargets; ENSG00000173175; -.
DR   Orphanet; 324588; Familial dyskinesia and facial myokymia.
DR   PharmGKB; PA24563; -.
DR   eggNOG; KOG3619; Eukaryota.
DR   eggNOG; COG2114; LUCA.
DR   GeneTree; ENSGT00760000119042; -.
DR   HOGENOM; HOG000006941; -.
DR   HOVERGEN; HBG050458; -.
DR   InParanoid; O95622; -.
DR   KO; K08045; -.
DR   OMA; FMCNSKD; -.
DR   OrthoDB; EOG091G05JR; -.
DR   PhylomeDB; O95622; -.
DR   TreeFam; TF313845; -.
DR   BRENDA; 4.6.1.1; 2681.
DR   Reactome; R-HSA-163359; Glucagon signaling in metabolic regulation.
DR   Reactome; R-HSA-163615; PKA activation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-170660; Adenylate cyclase activating pathway.
DR   Reactome; R-HSA-170670; Adenylate cyclase inhibitory pathway.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   SIGNOR; O95622; -.
DR   ChiTaRS; ADCY5; human.
DR   GeneWiki; ADCY5; -.
DR   GenomeRNAi; 111; -.
DR   PRO; PR:O95622; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000173175; -.
DR   CleanEx; HS_ADCY5; -.
DR   ExpressionAtlas; O95622; baseline and differential.
DR   Genevisible; O95622; HS.
DR   GO; GO:0005929; C:cilium; ISS:UniProtKB.
DR   GO; GO:0008074; C:guanylate cyclase complex, soluble; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0004016; F:adenylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0008179; F:adenylate cyclase binding; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004383; F:guanylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0097110; F:scaffold protein binding; IEA:Ensembl.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:Reactome.
DR   GO; GO:0034199; P:activation of protein kinase A activity; TAS:Reactome.
DR   GO; GO:0001973; P:adenosine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007189; P:adenylate cyclase-activating G-protein coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006171; P:cAMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:1904322; P:cellular response to forskolin; IDA:UniProtKB.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:UniProtKB.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   Gene3D; 3.30.70.1230; -; 2.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR032628; AC_N.
DR   InterPro; IPR030672; Adcy.
DR   InterPro; IPR009398; Adcy_conserved_dom.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   Pfam; PF16214; AC_N; 1.
DR   Pfam; PF06327; DUF1053; 1.
DR   Pfam; PF00211; Guanylate_cyc; 2.
DR   PIRSF; PIRSF039050; Ade_cyc; 1.
DR   SMART; SM00044; CYCc; 2.
DR   SUPFAM; SSF55073; SSF55073; 2.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 2.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; cAMP biosynthesis; Cell membrane;
KW   Cell projection; Cilium; Complete proteome; Disease mutation;
KW   Glycoprotein; Lyase; Magnesium; Membrane; Metal-binding; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1   1261       Adenylate cyclase type 5.
FT                                /FTId=PRO_0000195694.
FT   TOPO_DOM      1    195       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    196    216       Helical. {ECO:0000255}.
FT   TRANSMEM    242    262       Helical. {ECO:0000255}.
FT   TRANSMEM    268    288       Helical. {ECO:0000255}.
FT   TRANSMEM    299    319       Helical. {ECO:0000255}.
FT   TRANSMEM    325    345       Helical. {ECO:0000255}.
FT   TRANSMEM    374    394       Helical. {ECO:0000255}.
FT   TOPO_DOM    395    769       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    770    790       Helical. {ECO:0000255}.
FT   TRANSMEM    792    812       Helical. {ECO:0000255}.
FT   TRANSMEM    836    856       Helical. {ECO:0000255}.
FT   TOPO_DOM    857    909       Extracellular. {ECO:0000255}.
FT   TRANSMEM    910    930       Helical. {ECO:0000255}.
FT   TRANSMEM    935    955       Helical. {ECO:0000255}.
FT   TRANSMEM    984   1004       Helical. {ECO:0000255}.
FT   TOPO_DOM   1005   1261       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      469    596       Guanylate cyclase 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   DOMAIN     1071   1210       Guanylate cyclase 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   NP_BIND     474    479       ATP. {ECO:0000250|UniProtKB:P30803}.
FT   NP_BIND     516    518       ATP. {ECO:0000250|UniProtKB:P30803}.
FT   NP_BIND    1197   1199       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   NP_BIND    1204   1208       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   METAL       474    474       Magnesium 1; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   METAL       474    474       Magnesium 2; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   METAL       475    475       Magnesium 2; via carbonyl oxygen;
FT                                catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00099}.
FT   METAL       518    518       Magnesium 1; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   METAL       518    518       Magnesium 2; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00099}.
FT   BINDING     562    562       ATP. {ECO:0000250|UniProtKB:P30803}.
FT   BINDING    1123   1123       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   BINDING    1244   1244       ATP. {ECO:0000250|UniProtKB:P26769}.
FT   MOD_RES      23     23       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:P84309}.
FT   MOD_RES      96     96       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P84309}.
FT   MOD_RES     155    155       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P84309}.
FT   MOD_RES     666    666       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O43306}.
FT   MOD_RES     754    754       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q03343}.
FT   MOD_RES    1011   1011       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q03343}.
FT   CARBOHYD    870    870       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    887    887       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     28       MSGSKSVSPPGYAAQKTAAPAPRGGPEH -> MKSQKEGCC
FT                                SRGDLSIQTGPGGEWAPRR (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042914.
FT   VAR_SEQ      29    378       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042915.
FT   VARIANT     418    418       R -> W (in FDFM; increases cAMP
FT                                production upon activation of ADRB1;
FT                                dbSNP:rs864309483).
FT                                {ECO:0000269|PubMed:24700542}.
FT                                /FTId=VAR_073778.
FT   VARIANT     726    726       A -> T (in FDFM; increases cAMP
FT                                production upon activation of ADRB1;
FT                                dbSNP:rs796065306).
FT                                {ECO:0000269|PubMed:22782511,
FT                                ECO:0000269|PubMed:24700542}.
FT                                /FTId=VAR_068821.
SQ   SEQUENCE   1261 AA;  138908 MW;  C50492A0B053694F CRC64;
     MSGSKSVSPP GYAAQKTAAP APRGGPEHRS AWGEADSRAN GYPHAPGGSA RGSTKKPGGA
     VTPQQQQRLA SRWRSDDDDD PPLSGDDPLA GGFGFSFRSK SAWQERGGDD CGRGSRRQRR
     GAASGGSTRA PPAGGGGGSA AAAASAGGTE VRPRSVEVGL EERRGKGRAA DELEAGAVEG
     GEGSGDGGSS ADSGSGAGPG AVLSLGACCL ALLQIFRSKK FPSDKLERLY QRYFFRLNQS
     SLTMLMAVLV LVCLVMLAFH AARPPLQLPY LAVLAAAVGV ILIMAVLCNR AAFHQDHMGL
     ACYALIAVVL AVQVVGLLLP QPRSASEGIW WTVFFIYTIY TLLPVRMRAA VLSGVLLSAL
     HLAIALRTNA QDQFLLKQLV SNVLIFSCTN IVGVCTHYPA EVSQRQAFQE TRECIQARLH
     SQRENQQQER LLLSVLPRHV AMEMKADINA KQEDMMFHKI YIQKHDNVSI LFADIEGFTS
     LASQCTAQEL VMTLNELFAR FDKLAAENHC LRIKILGDCY YCVSGLPEAR ADHAHCCVEM
     GMDMIEAISL VREVTGVNVN MRVGIHSGRV HCGVLGLRKW QFDVWSNDVT LANHMEAGGK
     AGRIHITKAT LNYLNGDYEV EPGCGGERNA YLKEHSIETF LILRCTQKRK EEKAMIAKMN
     RQRTNSIGHN PPHWGAERPF YNHLGGNQVS KEMKRMGFED PKDKNAQESA NPEDEVDEFL
     GRAIDARSID RLRSEHVRKF LLTFREPDLE KKYSKQVDDR FGAYVACASL VFLFICFVQI
     TIVPHSIFML SFYLTCSLLL TLVVFVSVIY SCVKLFPSPL QTLSRKIVRS KMNSTLVGVF
     TITLVFLAAF VNMFTCNSRD LLGCLAQEHN ISASQVNACH VAESAVNYSL GDEQGFCGSP
     WPNCNFPEYF TYSVLLSLLA CSVFLQISCI GKLVLMLAIE LIYVLIVEVP GVTLFDNADL
     LVTANAIDFF NNGTSQCPEH ATKVALKVVT PIIISVFVLA LYLHAQQVES TARLDFLWKL
     QATEEKEEME ELQAYNRRLL HNILPKDVAA HFLARERRND ELYYQSCECV AVMFASIANF
     SEFYVELEAN NEGVECLRLL NEIIADFDEI ISEDRFRQLE KIKTIGSTYM AASGLNDSTY
     DKVGKTHIKA LADFAMKLMD QMKYINEHSF NNFQMKIGLN IGPVVAGVIG ARKPQYDIWG
     NTVNVASRMD STGVPDRIQV TTDMYQVLAA NTYQLECRGV VKVKGKGEMM TYFLNGGPPL
     S
//
